-
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to…
-
ICP DAS-BMP Brings Advanced Medical TPU Portfolio to Medical Manufacturing Asia 2026
HSINCHU, Aug. 25, 2026 /PRNewswire/ — ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), will exhibit at Medical Manufacturing Asia 2026, taking place September 9–11 at the Marina Bay Sands Expo & Convention Centre in Singapore (Booth 2U20). Exhibiting together with its manufacturing partner, Towards Buddha Co., Ltd., the…
-
TME Pharma provides update on its activities
TME Pharma enters final evaluation phase with two potential partners for licensing lead asset NOX-A12 to support Phase 2 glioblastoma development Source: TME Pharma provides update on its activities
-
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
TAIPEI, Aug. 24, 2026 /PRNewswire/ — Anbogen Therapeutics Inc. (TPEx: 7784) (“Anbogen” or the “Company”), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, to evaluate ABT-301 (Imofinostat), the Company’s selective…
-
Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
Orum receives FDA clearance for ORM-1153, advancing its novel CD123-GSPT1 degrader-antibody conjugate toward Phase 1 in hematologic malignancies. Source: Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
-
ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights
The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workflows, providing clinicians with more time for personalizing patient care. JENA, Germany, Aug. 19, 2026 /PRNewswire/ — ZEISS Medical Technology, one of the world’s leading medical technology companies, today announced the 510k clearance from the U.S.…
-
The Baja Is Back: A Race Against Blindness Offers One Final Chance to Win $350,000 Adventure Truck Prize
Race Against Blindness Offers One Final Chance to Win $350,000 Adventure Truck Prize Source: The Baja Is Back: A Race Against Blindness Offers One Final Chance to Win $350,000 Adventure Truck Prize
-
Apollo Hospitals launches ‘Always Open, Always Here’, a global first in healthcare from India
NEW DELHI, Aug. 20, 2026 /PRNewswire/ — Apollo Hospitals launched ‘Always Open. Always Here.’, a first-of-its-kind initiative that makes routine and planned healthcare services available across all seven days of the week, including Sundays. Apollo’s emergency, critical care and inpatient services have always been available 24×7. The new initiative extends Sunday access to outpatient consultations,…
-
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
PharmAla Biotech provides a corporate update relating to its investment banking partner, Canaccord Genuity LLC, and its IP. Source: PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
-
Colgate-Palmolive elevates Prabha Narasimhan to EVP – Marketing, Asia-Pacific and announces Manish Anandani as new MD & CEO for India
MUMBAI, India, Aug. 21, 2026 /PRNewswire/ — Colgate-Palmolive India Limited today announced a key leadership transition. Prabha Narasimhan, Managing Director and Chief Executive Officer, has been elevated to the role of Executive Vice President – Marketing, Asia-Pacific Division, Colgate-Palmolive, effective close of business hours on 27 September, 2026. To lead the company into its next growth phase, the Board of Directors has approved the appointment…
-
Grey Matters Achieves Final Major Milestone; Receives Radioactive Materials License from State of Florida for its Flagship NovaScan Neuroimaging Clinics™ Location
VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) — Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to announce that it has now received its Radioactive Materials License (RML) from the State of Florida for its flagship NovaScan Neuroimaging Clinics™ location (“NovaScan” or…
-
Dubai Police Initiatives Drive $176.4 Million in Social Value and Gains in Safety, Wellbeing and the Economy, Study Reveals
DUBAI, UAE, Aug. 19, 2026 /PRNewswire/ — A study has estimated the Social Return on Investment (SROI) of 80 Dubai Police community initiatives at AED 647.9 million ($176.4 million), reflecting the wider social, economic and security value created for 3.8 million beneficiaries between 2017 and 2026. Conducted by the Future Foresight Centre, the study examined initiatives across…
-
BC health research pursues precision, genetics-based care for three conditions
Genome BC-funded projects cover off-the-shelf pharmacogenetic testing, genetically-informed nutrition planning, and predicting therapies for blood cancers. Source: BC health research pursues precision, genetics-based care for three conditions
-
Cellebrite Genesis for Enterprise Now Generally Available, Regional Availability Expands to More Global Markets
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 19, 2026 /PRNewswire/ — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that Cellebrite Genesis is expanding to more global markets and is now generally available for enterprise organizations. The expansion builds…
-
Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 Source: Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
-
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ — GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results…
-
Cooper Clinic Introduces Digital Nutrition Platform
Cooper Clinic announces the addition of The Learning Plate digital platform to its nutrition services offerings, offering on-demand and virtual classes. Source: Cooper Clinic Introduces Digital Nutrition Platform
-
Herbalife Reinforces Commitment to Metabolic Wellness and Healthy Ageing at IISc’s RISE for Healthy Ageing Conference 2026
BENGALURU, India, Aug. 17, 2026 /PRNewswire/ — Herbalife, a premier health and wellness company, participated at the RISE for Healthy Ageing Conference 2026, hosted by the Longevity India Initiative at the Indian Institute of Science (IISc). The association reinforces Herbalife’s commitment to advancing healthy ageing through science-backed nutrition, metabolic wellness, innovation and collaboration. As India experiences…
-
GuideAI Health Corp. Announces Frankfurt Stock Exchange Symbol: ZN0
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) — GuideAI Health Corp. (“GuideAI” or the “Company“) (Cboe CA: GDAI) (FSE: ZN0) is pleased to announce its common shares are now posted on the Frankfurt Stock Exchange (“FSE”) under the symbol “ZN0”, WKN: A42EHA, and ISIN: CA CA40173G1019. Source: GuideAI Health Corp. Announces Frankfurt Stock Exchange Symbol: ZN0
-
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy Source: BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
-
Avicanna Reports Q2 2026 Financial Results
Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product salesQUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured Source: Avicanna Reports Q2 2026 Financial Results
-
More Cancer Patients Are Opting to Preserve Their Tumors
New Tumor-Preservation Service Opens in Arizona, Giving Patients the Chance to Preserve Tumor Tissue for Potential Personalized Dendritic Cell Therapy Source: More Cancer Patients Are Opting to Preserve Their Tumors
-
Axtria to Build Industry’s Largest Pharma-Specific AI Engineering Team, Scaling to 1,000 by December 2026
NEW DELHI, Aug. 13, 2026 /PRNewswire/ — Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced plans to expand its Forward Deployed Engineering (FDE) organization to 1,000 engineers by December 2026, creating the industry’s largest pharma-specific AI engineering team. The expansion represents one of Axtria’s largest investments in AI…
-
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2026, and provided a business…
-
ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
SHANGHAI, Aug. 13, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the Investigational New Drug (IND) application for AK0406 injection, the company’s first long-acting antiviral drug‑Fc conjugate (AFC) candidate for influenza prophylaxis, has been approved by the National Medical Products Administration (NMPA) of China, making AK0406 the first influenza AFC drug…
-
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares Source: FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
-
Helfie AI Appoints Heavyweight Tech and Governance Leaders to its Board of Directors
Former Apple and Airbnb executive Patrick Gates and ex-Meta executive Sunita Parasuraman join as Non-Executive Directors, strengthening Helfie’s technology and governance. MELBOURNE, Australia, Aug. 11, 2026 /PRNewswire/ — Helfie AI (“Helfie”), an AI-powered preventative network transforming global healthcare via mobile, today announced the appointment of Patrick Gates and Sunita Parasuraman as Non-Executive Directors. Patrick Gates…
-
MRG Group Announces Strategic Collaboration with Arica Pharmaceutical, Marking its Expansion into the Healthcare Ecosystem
New Delhi, Delhi, India MRG Group, a diversified business conglomerate, has announced its strategic collaboration with Arica Pharmaceutical, reinforcing its commitment to supporting India’s rapidly growing healthcare sector while fostering innovation, quality, and community well-being. MRG Group Announces Strategic Collaboration with Arica Pharmaceutical, Marking Its Expansion into the Healthcare Ecosystem The partnership brings together MRG…
-
PlatinumRx Helps Indians Save Crores on Medicines, Expands Access to Quality Branded Generics
Bengaluru, Karnataka, India PlatinumRx, one of India’s fast-growing branded generic medicine platforms, has helped its customers collectively save over crores on their medicine purchases by choosing high-quality branded generic alternatives. The platform has earned the trust of more than 10 lakh+ customers and now delivers medicines across 19,000+ PIN codes nationwide. PlatinumRx Helps Indians Save…
-
Morepen Clocks Highest-Ever Quarterly Revenue and Earnings in Q1'FY27; EBITDA Grows by 207% and PAT by 394%; CDMO Enters Full Scale Commercialization
Gurugram, Haryana, India Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) today announced its financial results for the quarter ended June 30, 2026, reporting its highest-ever quarterly revenue and highest-ever quarterly earnings, supported by better operating leverage, improved performance on API front, strong export growth and full scale commercialization of CDMO mandate. Morepen Q1FY27 Results Highlights…
-
Manipal University Jaipur Launches PCI-Approved B.Pharm. Programme, Admissions Open for 2026–27
Jaipur, Rajasthan, India Manipal University Jaipur (MUJ) has announced the launch of its Bachelor of Pharmacy (B.Pharm.) programme under the School of Pharmaceutical Sciences after receiving approval from the Pharmacy Council of India (PCI). Admissions for the inaugural 2026–27 academic session are now open for the aspiring students. Manipal University Jaipur The introduction of the…
-
Exor and Philips Extend Long-term Relationship Agreement
August 11, 2026 Source: Exor and Philips Extend Long-term Relationship Agreement
-
Manulife Appoints Jeremy Young as Chief Distribution Officer, International Brokerage, Global High-Net-Worth to Advance Growth Strategy Across Key Markets
HONG KONG, Aug. 11, 2026 /PRNewswire/ — Manulife announced the appointment of Jeremy Young as Chief Distribution Officer, International Brokerage, Global High-Net-Worth, effective immediately. Mr Young has served as Interim Chief Distribution Officer since March, providing strong leadership while advancing Manulife’s distribution strategy and deepening broker engagement across key markets. In his new role, he…
-
Chandigarh University’s 272 Allied Health Sciences Students Secure Jobs in Prestigious Govt & Private Hospitals in Past 3 Years
University Boosts Employability with Internships for 393 Allied Health Sciences Students at Top Health Institutions CHANDIGARH, India, July 25, 2026 /PRNewswire/ — Chandigarh: Chandigarh University (CU) students of Allied Health Sciences — Optometry, Forensic Science, Medical Laboratory Science, Nutrition and Dietetics and Physiotherapy – have secured over 272 jobs in leading corporate organisations and prestigious government…
-
ARCPOINT PROVIDES LEADERSHIP UPDATE
July 24, 2026 19:34 ET | Source: ARCpoint Inc. GREENVILLE, South Carolina, July 24, 2026 (GLOBE NEWSWIRE) — ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) announces today that Peter Kendall has stepped down as Interim Chief Executive Officer of the Company, having completed his mandate and delivered his assessment and recommendations to the Board…
-
ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406
SHANGHAI, July 24, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clinical trial has now entered the follow‑up phase. AK0406 is a novel long-acting…
-
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
July 23, 2026 21:08 ET | Source: Scribe Therapeutics Inc. ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) — Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial…
-
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics. Pharmaceuticals Division sales were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales…
-
Rajasthan’s cash-plus scheme linked to healthier birth weights, finds study published in Nature Health
Programme combining cash transfers with counselling associated with 7.4 percentage-point drop in low birthweight among 90,000+ newborns from tribal communities in southern Rajasthan JAIPUR, India, July 22, 2026 /PRNewswire/ — A Rajasthan state government-run maternal nutrition programme that paired conditional cash transfers with nutrition counselling and community outreach was associated with meaningfully better birth outcomes for…
-
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
July 22, 2026 02:00 ET | Source: Healx Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310, an investigational oral combination…
-
Apollo Hospitals Brings Next-Generation Lysin Science to India’s Fight Against AMR – Collaborates with Precisio Biotix
HYDERABAD, India, July 21, 2026 /PRNewswire/ — Apollo Hospitals today announced a strategic collaboration with Precisio Biotix to accelerate the development and clinical adoption of lysin-based antimicrobials in India – marking a significant step forward in combating antimicrobial resistance (AMR). This partnership will focus on translational research, clinical validation, and potential deployment pathways for lysin-based therapies across…
-
Allogenetics Appoints Dr. Jeroen Rovers as Chief Medical Officer
Seasoned executive leader and physician-scientist brings deep immunology and transplant medicine experience Company strengthens executive team as it advances its lead ex vivo donor-organ therapy ALG-115 toward clinical entry ALG-115 is designed to transform the treatment of graft rejection in lung transplantation Hanover, Germany, July 21, 2026 – Allogenetics today announced the appointment of Jeroen Rovers,…
-
Zydus Hospital, Ahmedabad’s Surgeons Reattach Toddler’s Severed Fingers in a 12-Hour Race Against Time
AHMEDABAD, India, July 21, 2026 /PRNewswire/ — Hand and limb trauma remains one of the most time-sensitive emergencies. Unlike many surgeries that allow for observation and planning, traumatic amputations and crush injuries operate on a strict biological clock as the tissues that are deprived of blood supply for too long cannot be saved. Correct handling…
-
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German regulatory authority, the Paul-Ehrlich-Institute (PEI), regarding the underlying biology and proposed non-clinical development plan for its most-advanced development program based on its proprietary…
-
Fostering new opportunities in the Greater Bay Area and Asia’s Pharmaceutical Industry
SHANGHAI, July 20, 2026 /PRNewswire/ — Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on this momentum, CPHI & PMEC Shenzhen 2026 will take place from 16-18…
-
Burntide Gummies Launch 2026 | Advanced Weight Loss Formula Highlights Ingredients, Supplement Facts Available in USA, UK, CA, By BurnTide.
New York City, July 19, 2026 (GLOBE NEWSWIRE) — In 2026, we are proud to announce the launch of Burntide, a truly effective natural gummy thoughtfully designed to support your weight loss journey while supporting your overall health and well-being. Burntide gummies combine a unique and powerful blend of premium, natural ingredients, carefully selected to…
-
Vireo Growth Inc. Completes Acquisition of Pennsylvania Dispensary License Transaction
MINNEAPOLIS, July 17, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that it has completed its previously announced acquisition of all of the issued and outstanding limited liability company membership interests of FarmX, LLC d/b/a PhytoNatural (“PhytoNatural”), jointly with Vive Penn, LLC (“Vive”), a joint venture…
-
Skyline LASIK Introduces WaveLight® Plus LASIK, Advancing Precision in Vision Correction
New data presented at the American Academy of Ophthalmology highlights enhanced visual outcomes with next-generation LASIK technology July 17, 2026 12:00 ET | Source: Skyline LASIK Colorado Springs, CO, July 17, 2026 (GLOBE NEWSWIRE) — Skyline LASIK is proud to announce the availability of WaveLight® Plus LASIK, an advanced, ray-tracing guided technology designed to deliver…
-
Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases
CHICAGO, July 16, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 250,000 shares of its common stock in the open market at an average price of approximately $0.2782 per share. The Company has now repurchased a…
-
The Silent Sleep Crisis: Apollo Experts Warn That 80-90% of Sleep Apnoea Cases Go Undiagnosed
Apollo Hospitals Navi Mumbai urges citizens not to ignore loud snoring and excessive daytime sleepiness as it launches a dedicated Sleep Disorders Clinic NAVI MUMBAI, India, July 16, 2026 /PRNewswire/ — Sleep disorders are emerging as one of the most overlooked public health concerns in the Mumbai Metropolitan Region (MMR), with experts estimating that nearly…
-
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
FREMONT, Calif., July 15, 2026 (GLOBE NEWSWIRE) — Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the opening of a new innovation center in Bellevue, Washington, marking the relocation of its previous Seattle-area operations to a dedicated facility designed to support research and development (R&D) while strengthening collaboration and customer engagement. The…
-
Metabolon Expands Microbiome Panel to Strengthen Industry Leadership in Functional Microbiome Research
Enhanced panel screens for more than 800 microbiome-associated metabolites, giving researchers a broader view of microbial activity linked to human health, nutrition, disease, and treatment response MORRISVILLE, N.C., July 15, 2026 /PRNewswire/ — Metabolon, Inc., the global leader in metabolomics solutions advancing life science research, diagnostics, therapeutics, and precision medicine, today announced an expansion of…
-
Spire Healthcare announced as exclusive Team GB Official Healthcare Services Partner
Organisations join forces for “a healthier, more productive nation” Agreement with Team GB covers the Los Angeles 2028 Olympic Games LONDON, July 15, 2026 (GLOBE NEWSWIRE) — Spire Healthcare today announces a new strategic partnership with Team GB, becoming the team’s exclusive Official Healthcare Services Partner through to the end of 2028, including the Los…
-
NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists’ Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act
WASHINGTON, July 14, 2026 /PRNewswire/ — On July 14, 2026, the U.S. Fish and Wildlife Service (“USFWS”) for the second time declined to accept a petition filed by People for the Ethical Treatment of Animals (“PETA”) and other activist groups to list long-tailed macaque (“LTM”) monkeys (Macaca fascicularis) under the U.S. Endangered Species Act (“ESA”). The…
-
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
July 13, 2026 20:35 ET | Source: Mesoblast Limited NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L…
-
IMG Opens Applications for 2026 Fall Semester ‘Student Journey Scholarship’
INDIANAPOLIS, July 13, 2026 /PRNewswire/ — IMG (International Medical Group) is now accepting applications for its Student Journey Scholarship, a program designed to help international students fund their studies at a U.S. college or university. Entries for the 2026 Fall semester will be accepted July 13-October 4, 2026, and one student will be selected to…
-
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners July 12, 2026 11:18 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data…
-
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2026
FORMER ELITE SOCCER PLAYERS SHOWEVIDENCE OF BRAIN HEALTH CHANGES IN MID-LIFE Key Takeaways New research provides insights into brain health among former elite professional soccer players during midlife. Former players reported high levels of depression, anxiety, and subjective difficulties with thinking and decision-making. Researchers found brain differences that warrant further study. The findings highlight the…
-
GuideAI Health Announces Marketing and Communications Programs
July 10, 2026 17:01 ET | Source: GuideAI Health Corp. BOSTON, July 10, 2026 (GLOBE NEWSWIRE) — GuideAI Health Corp. (Cboe CA: GDAI) (“GuideAI” or the “Company“) is pleased to announce that it has engaged Upswitch Media Corp. (“Upswitch”) and BTV-Business Television (“BTV”) — to execute a coordinated marketing, communications and investor-awareness program (the “Program”). The…
-
Horse Boost Gummies For Men 2026 Launch Featuring the Viral Horse Gelatin Salt Trick Recipe Male Enhancement Support By HorseBoost
New York City, July 11, 2026 (GLOBE NEWSWIRE) — In 2026, Horse Boost announces a new Gummies formula that takes a science-inspired approach to male health performance by focusing on a thoughtfully developed combination of ingredients commonly used in dietary supplements for supporting energy, vitality, stamina, circulation, stress management, and performance well-being. The formulation reflects…
-
Happiest Health Announces Launch of Speciality Clinics: Happiest Paediatrics, Happiest Orthopaedics, Happiest Gynaecology, Happiest Endocrinology & Your Personal Physician
BENGALURU, India, July 9, 2026 /PRNewswire/ — Happiest Health is happy to announce the launch of Speciality Clinics, Happiest Paediatrics, Happiest Orthopaedics, Happiest Gynaecology, Happiest Endocrinology & Your Personal Physician in Koramangala, Bengaluru, marking its entry into neighbourhood healthcare. This represents a significant expansion of the company’s healthcare ecosystem, bringing consultations, diagnostics, and pharmacy services together…
-
Canadian Red Cross opens appeal to support people impacted by flooding in Manitoba
WINNIPEG, Manitoba, July 10, 2026 (GLOBE NEWSWIRE) — The Canadian Red Cross has launched the 2026 Manitoba Floods Appeal to provide support for those impacted by flooding in Manitoba. Donations to the Canadian Red Cross will be used to provide assistance to those impacted by the flooding in Manitoba with immediate and ongoing relief, recovery, and…
-
Garware Fulflex Completes Acquisition of 300,000-Square-Foot Fully Automated Medical Products Manufacturing Facility in The United States
PUNE, India and JACKSONVILLE, Texas, July 10, 2026 /PRNewswire/ — Garware Fulflex today announced the successful completion of its acquisition of a 300,000-square-foot, fully automated medical products manufacturing facility in Jacksonville, Texas, marking a major milestone in the company’s global healthcare growth strategy and significantly expanding its manufacturing footprint in North America. Situated on a…
-
No easy answers: European research consortia take on major challenges
COPENHAGEN, Denmark, July 10, 2026 (GLOBE NEWSWIRE) — Nine new Challenge Programme grants from the Novo Nordisk Foundation will support ambitious research across fungal diseases, cardiometabolic disease, soil health and non-equilibrium biological systems. With a European expansion, the 2026 awards unite strong research groups and diverse expertise across Europe in the pursuit of novel knowledge…
-
Guwahati Gets a Life-Saving Heart Breakthrough: Apollo Hospitals Performs Northeast India’s First LAA Closure
Recognised as one of the Best Cardiology Hospitals in Guwahati, Apollo’s expert team brings new hope to patients who cannot safely take blood-thinning medicines GUWAHATI, India, July 9, 2026 /PRNewswire/ — A silent but life-saving battle was won recently in Guwahati. Doctors at Apollo Hospitals Guwahati – widely regarded as the Best Hospital in Guwahati for…
-
NTG Nordic Transport Group A/S – H1 2026 Conference Call
July 09, 2026 04:00 ET | Source: NTG Nordic Transport Group A/S NTG Nordic Transport Group A/S – H1 2026 Conference Call We expect to release the H1 2026 interim results of NTG Nordic Transport Group on the evening of August 10, 2026. A webcast and conference call will be held in the morning of…
-
Star Health’s Arogya Seva Kendras support over 6,830 beneficiary visits across Punjab, bringing free primary healthcare closer to communities
Star Health currently operates three Arogya Seva Kendras in Punjab across Amritsar, Bhatinda and Patiala Launched in January 2026, the three centres together have supported over 6,830 beneficiary visits Diabetes, fever, hypertension and respiratory illnesses are among the common cases seen at the centres, underlining the need for accessible neighbourhood-level healthcare PATIALA, India, July 9, 2026…
-
BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities
Proposed acquisition of an Israeli company with approximately 20 years of operating experience is expected to strengthen BiomX’s Detection-Analysis-Response strategy through security systems, fire detection, access control, intrusion detection, building-control, electrical infrastructure and secure-site integration capabilities July 08, 2026 07:05 ET | Source: BiomX NETANYA, Israel, July 08, 2026 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
-
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
July 07, 2026 09:12 ET | Source: Alamar Biosciences, Inc. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program…
-
Medicine Beyond Borders: Zydus Hospital, Ahmedabad, Emerges as a Preferred Destination for International Patients
AHMEDABAD, India, July 7, 2026 /PRNewswire/ — Quality healthcare should never be a matter of geography or means, yet for patients in many parts of the world, it still is. As illnesses grow more complex and treatments advance, the gap between what is medically possible and what is locally accessible keeps widening for many. Patients travelling…
-
Zealand Pharma – Transactions related to share buy-back program (week 27, 2026)
Company announcement No. 31 / 2026 Zealand Pharma – Transactions related to share buy-back program (week 27, 2026) Copenhagen, Denmark, July 6, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the…
-
World’s First International Patient Begins Treatment with Newly Approved Solid Tumor CAR-T Therapy at Jiahui International Cancer Center
SHANGHAI, July 6, 2026 /PRNewswire/ — Jiahui International Cancer Center (JICC) has welcomed the world’s first international patient to begin treatment with Satri-cel, the world’s first approved CAR-T therapy for a solid tumor, marking a historic milestone in expanding global access to China’s latest oncology innovations. Josh, a 59-year-old patient from New Zealand with advanced…
-
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the…
-
STARMED Receives FDA 510(k) Clearance for a Benign Thyroid Nodule Ablation Indication
SEOUL, South Korea, July 1, 2026 /PRNewswire/ — STARMED, a medical device company specialising in minimally invasive treatment technologies, has announced that it has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for a thyroid-specific indication (510(k) number: K252833). The clearance took effect on 26 May 2026. The company’s system may now…
-
Mark Leeds, D.O. PA Launches FloridaTaper.com, a Free Educational Resource on Benzodiazepine Tapering, Withdrawal, and BIND
The new website from Mark Leeds, D.O. PA offers more than 60 physician-written articles, with new articles published daily, for patients, families, and clinicians navigating slow benzodiazepine dose reductions. July 03, 2026 18:58 ET | Source: Mark Leeds, DO PA Fort Lauderdale, FL, July 03, 2026 (GLOBE NEWSWIRE) — Mark Leeds, D.O. PA, a Florida…
-
Velo x McLaren Mastercard Formula 1® Team Relaunches Live Your Fandom to Bring Fans Closer to the Sport They Love
LONDON, July 4, 2026 /PRNewswire/ — New research* commissioned by Velo highlights the lengths fans go to stay connected to the sports and teams they love, reinforcing the brand’s belief that fandom is an important form of self-expression. Building on this insight, Velo x McLaren Mastercard Formula 1® Team is relaunching Live Your Fandom for a second year —…
-
Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
July 03, 2026 16:30 ET | Source: Teladoc Health, Inc. NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee. Effective July 1, 2026, in connection with commencing employment as Head of Product of…
-
NYSE Content Update: Mobility Global Marks First Day as Public Company
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 1, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on July 1st…
-
Jelly Force Male Enhancement Gummies Release Latest Formula for Men: JellyForce Unique Ingredient Profile Report
Pinellas Park, FL, July 02, 2026 (GLOBE NEWSWIRE) — These statements have not been evaluated by the Food and Drug Administration. JellyForce is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use, especially if currently taking prescription medications. JellyForce is a gummy dietary supplement formulated for men,…
-
Saroj Super Speciality Hospital Inaugurated in Nava Raipur
NAVA RAIPUR, India, July 2, 2026 /PRNewswire/ — Saroj Super Speciality Hospital, a unit of Ganesh Das Chawla Charitable Trust, formally inaugurated its new healthcare facility in Nava Raipur, Chhattisgarh, marking a significant step towards strengthening access to quality healthcare in the region. With a legacy of over 27 years in healthcare, Saroj Hospital has expanded…
-
GNI Group Completes Acquisition of AYUMI Pharmaceutical
TOKYO, July 01, 2026 (GLOBE NEWSWIRE) — GNI Group Ltd. (TSE: 2160, “GNI Group” or the “Company”) today announced that it has completed the acquisition of all shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone. As a result, Ayumi Pharmaceutical Holdings Co., Ltd. and its subsidiary, Ayumi Pharmaceutical Co., Ltd. (“Ayumi…
-
Bredehorst Clinic Medical Management, Germany’s Leading Healthcare Procurement Specialist, partners with Sigla
DÜSSELDORF, Germany, July 1, 2026 /PRNewswire/ — Düsseldorf – Sigla, a European private equity firm, is pleased to announce its investment in Bredehorst Clinic Medical Management GmbH (“BCMM” or “the Company”), Germany’s leading provider of tech-enabled procurement optimisation services for hospitals and care facilities. BCMM improves the purchasing of German healthcare providers, particularly hospitals, by…
-
Morepen Starts Commercial Supplies Under its Rs. 825 Crore CDMO Mandate; First Rs. 50 Crore Dispatch Already Completed in Q1FY2026-27
Gurugram, Haryana, India Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) today issued an update on its recently announced Rs. 825 crore CDMO mandate. The first commercial dispatch, valued at approximately Rs. 50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation…
-
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
June 30, 2026 20:38 ET | Source: Mesoblast Limited NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) and has requested a…
-
Basecamp Research brings EDEN’s antibiotic and vaccine design models to Claude Science
Scientists can now design potent antibiotics and rapidly prioritise vaccine targets through Claude Science, thanks to integration with Basecamp Research’s EDEN models. LONDON and CAMBRIDGE, Mass., June 30, 2026 /PRNewswire/ — Basecamp Research today announced that its antibiotic design and vaccine target prediction EDEN models are now available through Claude, including Claude Science, Anthropic’s AI…
-
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study Sanofi intends to submit the data to support a regulatory application in the…
-
GLOBAL MITOCHONDRIAL HEALTH SUMMIT 2026 POSITIONS MITOCHONDRIAL HEALTH AS THE FOUNDATION OF HEALTHSPAN
Sydney and Kuala Lumpur events unite world-leading experts as Mitochondrial Health gains recognition as a defining force in healthy ageing, and healthspan Researchers and clinicians identify Ubiquinol as a foundational nutrient in the Mitoceuticals category, supporting mitochondrial function throughout life, from preconception to healthy ageing SYDNEY, June 29, 2026 /PRNewswire/ — The inaugural global Mitochondrial Health…
-
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa Hopledo® is already approved and marketed in the United States as CREXONT®, providing established regulatory and commercial experience as the therapy advances toward European approval More than…
-
A ‘founding father of fitness’ – Les Mills Snr 1934 – 2026
AUCKLAND, New Zealand, June 29, 2026 /PRNewswire/ — We pay heartfelt tribute to our founder, Les Mills Snr, who passed away peacefully today, aged 91. A Kiwi icon, Les blazed a trail in sport, business, politics and life. Together with his wife Colleen, he created a fitness dynasty, first through the Les Mills New Zealand (LMNZ)…
-
TBoostExperts.com Announces Availability of 2026 Consumer Report on Testosterone Booster Supplements and Men’s Health Supplement Evaluation
NEW YORK,USA, June 27, 2026 (GLOBE NEWSWIRE) — TBoostExperts.com today announced the availability of its 2026 Consumer Research Report on testosterone booster supplements and men’s health supplement evaluation, a newly published educational resource developed to help adult consumers better understand how to review supplement labels, ingredient disclosures, dosage transparency, product claims, and company information before…
-
Frost & Sullivan Institute Honors Organizations Driving Transformative Impact Through Visionary Leadership
SILICON VALLEY, Calif., June 26, 2026 /PRNewswire/ — The Frost & Sullivan Institute is proud to announce the recipients of the 2026 Visionary Growth Leadership Best Practices Recognition, honoring organizations that are setting new benchmarks for business leadership by tackling some of the world’s most critical challenges. This recognition celebrates enterprises that have successfully aligned…
-
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and…
-
EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
GENEVA, June 27, 2026 /PRNewswire/ — Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of developing dementia than those who do not, according to new research presented at the European Academy of Neurology (EAN) Congress 2026. Hearing loss is widely recognised as the largest modifiable risk…
-
As 'Substandard' Medicine Alerts Rise Sharply, Medkart Pharmacy Promotes Radical Transparency
With India’s drug regulator flagging a record number of medicines as ‘Not of Standard Quality’ in 2025, Medkart spotlights its Medkart Assured program – independent plant audits, dual third-party lab testing, and a pledge to publish its own quality data Ahmedabad, Gujarat, India Medicine quality has become one of the country’s most closely watched health…
-
Thought Leadership & Innovation Foundation Founder Bill Oldham Launches New Book: Beyond Better Data: What Actually Changes Health Care?
MCLEAN, Va., June 26, 2026 (GLOBE NEWSWIRE) — The Thought Leadership & Innovation Foundation (TLI) proudly announces the release of Beyond Better Data: What Actually Changes Health Care? a new book by Founder and Chairman Bill Oldham that brings together decades of experience in innovation, leadership, healthcare transformation, and the practical application of emerging technologies to…
-
Rare Neuro Emergency after Spinal Tumor Surgery Turns Critical, Ends in Successful Recovery at Zydus Hospital, Ahmedabad
Mother of two, saved after a whirlwind of physical turmoil AHMEDABAD, India, June 26, 2026 /PRNewswire/ — A 35-year-old woman, mother of one, had persistent lower back pain for a very long time. However, in the second pregnancy the pain became relatively severe where even doctors were unable to administer spinal anaesthesia. She delivered a healthy…
-
Commure Named “Overall NLP Company of the Year” in 2026 AI Breakthrough Awards
MOUNTAIN VIEW, Calif., June 25, 2026 (GLOBE NEWSWIRE) — Commure, a leading healthcare technology company, today announced it has been named “Overall NLP Company of the Year” in the 2026 AI Breakthrough Awards. The annual awards program recognizes the world’s most innovative companies, technologies, and products in artificial intelligence. Selected from more than 5,000 nominations…
-
Doctors at HCMCT Manipal Hospital Dwarka perform a life-saving heart bypass and robotic lung cancer surgery in a single session
NEW DELHI, June 25, 2026 /PRNewswire/ — Doctors at HCMCT Manipal Hospital Dwarka successfully performed a rare life-saving procedure on a 66-year-old man diagnosed with both coronary artery disease and lung cancer. While being examined for the cancer, the patient reported constant breathlessness and was found to have severe blockages in the arteries, along with cancer…
-
The Developing Doctor Launches CME-Accredited Course to Enhance Physician Wellbeing
Iowa City, IOWA, June 24, 2026 (GLOBE NEWSWIRE) — The Developing Doctor has unveiled its latest self-paced course, “Mastery & Wellness: How to Thrive as a Physician,” now approved for 12 physician CME credits. This course is jointly provided with the Postgraduate Institute for Medicine (PIM), making it eligible for reimbursement through most institutional CME…
-
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)
YOKOHAMA, Japan, June 24, 2026 /PRNewswire/ — REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.